Aardvark Therapeutics, Inc. Common Stock (AARD)
- Previous Close
7.93 - Open
8.01 - Bid 9.95 x 100
- Ask 10.31 x 100
- Day's Range
8.01 - 10.29 - 52 Week Range
4.88 - 19.58 - Volume
51,252 - Avg. Volume
160,950 - Market Cap (intraday)
219.563M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.96 - Earnings Date Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.50
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
aardvarktherapeutics.comRecent News: AARD
View More
Performance Overview: AARD
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AARD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AARD
View MoreValuation Measures
Market Cap
219.56M
Enterprise Value
146.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.35%
Return on Equity (ttm)
-50.70%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-20.59M
Diluted EPS (ttm)
-0.96
Balance Sheet and Cash Flow
Total Cash (mrq)
73.66M
Total Debt/Equity (mrq)
1.08%
Levered Free Cash Flow (ttm)
-10.67M